Iovance Biotherapeutics IOVA 深 沪
已收盘 12-24 16:00:00 美东时间
2.87
+0.050
+1.77%
华盛通- 最 高2.95
- 今 开2.83
- 成交量 768.44万股
- 最 低 2.83
- 昨 收 2.82
- 总市值 11.39亿
- 52周最高 8.15
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 1.6385
- 委 比 -94.50%
- 总股本 3.97亿
- 历史最高 54.208
- 量 比 0.43
- 振 幅 4.26%
- 历史最低 1.6385
- 每 手 1
- 风险率 1.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted stock options covering 43,150 shares to four new, non-executive employees on December 18, 2025. The options were granted under the Amended and Restated 2021 Inducement Plan and have an exercise price of $2.46, the closing price of the Company’s common stock on the grant date. Each stock option vests over a three-year period, with one-third vesting on the first anniversary of the employee’s start date and the remain...
12-19 22:15
美股牛股 | Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%
Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%，与Coursera合并以扩大全球AI教育市场份额>>
12-18 19:07
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $10
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $9 to $10.
12-18 01:45
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $9
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $4 to $9.
11-24 22:30
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted 164,900 stock options to 11 new, non-executive employees on November 20, 2025, under its 2021 Inducement Plan. Each option has an exercise price of $2.18 and vests over three years. Iovance focuses on developing TIL therapies for cancer.
11-21 22:15
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
11-08 02:04
